Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Recruiting 30Active not recruiting 25Completed 17Not yet recruiting 4Withdrawn 3Terminated 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4

Conditions

Waldenstrom Macroglobulinemia 2Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Lymphoma 1

Interventions

Specimen Handling 76Cisplatin 64Drug Therapy 63Carboplatin 63Bevacizumab 63Magnetic Resonance Spectroscopy 59Radiotherapy 57Gemcitabine 54Cyclophosphamide 54pembrolizumab 52Oxaliplatin 49Capecitabine 49toripalimab 44Paclitaxel 40tislelizumab 39Standard of Care 39fludarabine 36Injections 34Fluorouracil 34Biopsy 34venetoclax 33Blood Specimen Collection 31Immune Checkpoint Inhibitors 30anlotinib 28Nivolumab 28Surgical Procedures, Operative 27Irinotecan 27Docetaxel 27Leucovorin 26Dexamethasone 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Not yet recruiting × Bendamustine Hydrochloride × 1 year × Clear all
NCT07593482 2026-05-18

FC-BALANCE

Swiss Cancer Institute

Phase 2 Not yet recruiting
92 enrolled
Lymphoid

Lymphoma, B-Cell

NCT07259122 2025-12-02

ZBR in WM

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Not yet recruiting
43 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

NCT07206264 2025-10-03

ADAPT-MCL

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
45 enrolled
Lymphoid

Lymphoma, Lymphoma, Mantle-Cell

NCT07169565 2025-09-11

Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia

Institute of Hematology & Blood Diseases Hospital, China

Phase 1 Not yet recruiting
21 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡